Tricyclic inhibitors of poly(ADP-ribose) polymerases

Details Tricyclic inhibitors of poly(ADP-ribose) polymerases Tricyclic inhibitors of poly(ADP-ribose) polymerases

2005-09-06

2008-09-30

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S220000, C514S411000

Reexamination Certificate

active

07429578

ABSTRACT:
Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease.As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

REFERENCES:
patent: 3642820 (1972-02-01), Hester et al.
patent: 3883590 (1975-05-01), Schmerling
patent: 3900477 (1975-08-01), Philipp et al.
patent: 3932406 (1976-01-01), Buttner et al.
patent: 3950343 (1976-04-01), Philipp et al.
patent: 3978066 (1976-08-01), Philipp et al.
patent: 4033960 (1977-07-01), Seng et al.
patent: 4910193 (1990-03-01), Buchheit
patent: 5215738 (1993-06-01), Lee et al.
patent: 5246933 (1993-09-01), Turnbull et al.
patent: 5272143 (1993-12-01), Benson et al.
patent: 5342946 (1994-08-01), Hamilton
patent: 5587384 (1996-12-01), Zhang et al.
patent: 5589483 (1996-12-01), West
patent: 5659082 (1997-08-01), Flitter et al.
patent: 5756510 (1998-05-01), Griffin et al.
patent: 5756548 (1998-05-01), Flitter et al.
patent: 0018493 (1980-11-01), None
patent: 0 525 584 (1992-07-01), None
patent: 2297089 (1996-07-01), None
patent: 57144286 (1982-09-01), None
patent: 6434988 (1989-02-01), None
patent: WO 9509159 (1995-04-01), None
patent: WO 9524379 (1995-09-01), None
patent: WO 9526186 (1995-10-01), None
patent: WO 9704771 (1997-02-01), None
patent: WO 9719934 (1997-06-01), None
patent: WO 9732576 (1997-09-01), None
patent: WO 9833802 (1998-08-01), None
patent: WO 9851307 (1998-11-01), None
patent: WO 9851308 (1998-11-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 9911622 (1999-03-01), None
patent: WO 9911623 (1999-03-01), None
patent: WO 9911624 (1999-03-01), None
patent: WO 9911628 (1999-03-01), None
patent: WO 9911644 (1999-03-01), None
patent: WO 9911645 (1999-03-01), None
patent: WO 99/59975 (1999-11-01), None
patent: WO 9959973 (1999-11-01), None
patent: WO 9959975 (1999-11-01), None
patent: WO 97/04771 (2000-02-01), None
patent: WO 01/23386 (2001-04-01), None
patent: WO 01/23390 (2001-04-01), None
Zhang, J., “PARP inhibition: a novel approach to treat ischaemia/reperfusion and inflammation-related injuries,”Emerging Drugs: The Prospect for Improved Medicines, 209-221, (1999).
Love el at., “Neuronat accumutation of poty(ADP-ribose) after brain ischaemia,”Neuropathology and Applied Neurobiology, 25, 98-103 (1999).
Mandir el at., “Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism,”Proc. Natl. Acad. Sci. USA 96, 5774-5779 (1999).
Pieper et at., “Poty(ADP-ribose) potymerase, nitric oxide, and cett death,”Trends Pharmacofg. Sci., 20: 171-181 (1999).
Burkart et at., “Mice tacking the poty(ADP-ribose) potymerase gene are resistanl lo pancreatic beta-cetl destruction and diabetes devetopmenl induced by streplozocin,”Nature Medicine, 5, 314-319 (1999).
Kamenka et at., “Syntheses en Serie de ta Celo 6 imidazo [4,5,t-ij] quinoteine,”Chem. 10: 459 (1973).
Higgins, J., “Benzimidazote Potymers from Atdehydes and Tetreamines,”Journal of Polymer Science, Part A-I, 8, 171-177 (1970).
Imei, Y., “Facite Syntheses of 2H-t,2,4-Benzothiadiazine t,t-Dioxides and 4-Oxo-3,4-Dihydroquinazotines from 2-Aminobenzenesulfonamide or 2-Aminobenzamide and Atdehydes in the Presence of Sodium Hydrogen Sutfite,”Synthesis, 35-36 (Jan. 1981).
Ackerty, N., “A Novet Approach to Dual-Acting Thromboxane Receptor Antagonist/Synthase Inhibilors Based on the Link of t,3-Dioxane-Thromboxane Receptor Antagonists and Thromboxane Synthase Inhibilors,”J. Med. Chem 38, 1608-1628 (1995).
Breslin et al., “Synthesis and Anti-HIV-t Activity of 4,5,6,7-Tetrahydro-5-methylimidazo-[4,5,t-jk][t,4]benzodiazein-2(tH)-one (TIBO) Derivatives,”J. Med. Chem. 38, 771-793 (1995).
Szabo et al., “Protection against peroxynitrite-induced fibroblasl injury and arthritis devetopmenl by inhibition of poty(ADP-ribose) synthase,”Proc. Natl. Acad. Sci. USA 95, 3867-3872 (Mar. 1998).
Meryenoff et al., “Potential Anxiolytic Agents. Pyrido [t,2-a)] benzimidazoles: A New Structural Class of Ligands for the Benzodiazepine Binding Site on GABA-A Receptors,”J. Med. Chem. 38, 16-20 (1995).
Prox et at., “Rapid Structure Elucidation of Drug Metabotiles by Use of Stabte Isotopes,”Xenobiotica, 3(2), 103-112 (1973).
Choi, “At the Scene of Ischemic Brain Injury: Is PARP a Perp?,”Nature Medicine, 3(10), 1073-1074 (1997).
Sculley et al., “The determination of kinetic constants governing the slow, tight-binding inhibition of enzyme-catalysed reactions,”Biochimica et Biophysica Acta, 874, 44-53 (1986).
Pullen et al., “Chiral separation retention mechanisms in high-performance liquid chromatography using bare silica stationary phase and β-cyclodextrin as a mobile phase additive,”Journal of Chromatography A, 691, 187-193 (1995).
Pullen et al., “Direct Determination of Substituted Azepinoindole Enantiomers in Rat Plasma Using Silica Stationary Phase and β-Cyclodextrin as a Mobile Phase Additive,”Analytical Chemistry, 67, 1903-1906 (1995).
Griffin et al., “Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP),”Anti-Cancer Drug Design, 10, 507-514 (1995).
Naidong et al., “Stereospecific determinations of (±)-DU-124884 and its metabolites (±)-KC-9048 in human plasma by liquid chromatography,”Journal of Pharmaceutical and Biomedical Analysis, 14, 325-337 (1996).
Zingarelli et al., “Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase,”Cardiovascular Research, 36, 205-215 (1997).
Hayashi et al., “Induction of hepatic poly (ADP-ribose) polymerase by peroxisome proliferators, non-genotoxic hepatocarcinogens,”Cancer Letters, 127, 1-7 (1998).
Bowes et al., “Effects of inhibitors of the activity of poly (ADP-ribose) synthetase on the liver injury caused by ischaemia-reperfusion: a comparison with radical scavengers,”British Journal of Pharmacology, 124, 1254-1260 (1998).
Szabo et al., “Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion,”TiPS, 19, 287-298 (1998).
Simonin et al., “Identification of Potential Active-site Residues in the Human Poly (ADP-ribose) Polymerase,”The Journal of Biological Chemistry, 268(12), 8529-8535 (1993).
Marsischky et al., “Role of Glutamic Acid 988 of Human Poly-ADP-ribose Polymerase in Polymer Formation,”The Journal of Biological Chemistry, 270(7), 3247-3254 (1995).
Eliasson et al., “Poly (ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia,”Nature Medicine, 3(10), 1089-1095 (1997).
Cosi et al., “Poly (ADP-Ribose) Polymerase (PARP) Revisited,Annals New York Academy of Sciences,” 366-379 (1997).
Sawant et al., “Synthesis of Some Pentacyclic Quinoxalines,”J. Shivaji Univ.(Science), 17, 63-65 (1977).
Bowman et al., “1,3,4,5-Tetrahydrobenz[cd] indoles and Related Compounds. Part II,”J.C.S. Perkin I, 1926-1932 (1972).
Ananthanarayanan et al., “3,4-Bridged Indoles: Part II-Synthesis of 6-Keto-I,5-dihydro-4,5-diazepino[6,5,4-cd]indoles & 3,4-Disubstituted Indoles as 5-HT Antagonists,”Indian Journal of Chemistry, 15B, 710-714 (1977).
Segel,Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, ch. 3, John Wiley and Sons, Inc., 100-125 (1975).
Gall et al., “Syntheses of 7-Substituted Indoline Derivatives,”Journal, 20, 1538-1544 (1955).
Somei et al., “The Chemistry of Indoles. XLIV. Synthetic Study Directed toward 3,4,5,6-Tetrahydro-1H-azepino[5,4,3-cd] indoles,”Chem. Pharm. Bull, 36(3), 1162-1168 (1988).
Clark et al., “1,9-Alkano-Bridged 2

Affiliated with

Also associated with

Rating

Tricyclic inhibitors of poly(ADP-ribose) polymerases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tricyclic inhibitors of poly(ADP-ribose) polymerases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic inhibitors of poly(ADP-ribose) polymerases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3968316